4-Allyloxy-N-hydroxy-benzamidine | 1011264-15-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Allyloxy-N-hydroxy-benzamidine
• 英文别名: N'-hydroxy-4-prop-2-enoxybenzenecarboximidamide
• CAS: 1011264-15-5
• 化学式: C₁₀H₁₂N₂O₂
• 分子量: 192.217
• InChiKey: ZOUFGZOMBQONHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Allyloxy-N-hydroxy-benzamidine 在 sodium methylate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 1-(3-(4-(3-(4-(allyloxy)phenyl)-1,2,4-oxadiazol-5-yl)-5-amino-1H-1,2,3-triazol-1-yl)phenyl)ethan-1-one oxime
  参考文献：
  名称：

  Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan

  摘要：

  Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a > 10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.

  DOI：

  10.1021/acs.jmedchem.7b01891
• 作为产物：
  描述：

  4-(烯丙氧基)苯甲腈 在 盐酸羟胺 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 6.0h， 以75%的产率得到4-Allyloxy-N-hydroxy-benzamidine
  参考文献：
  名称：

  离子印迹聚合物，用于从稀土混合物中选择性分离铈（III）离子

  摘要：

  离子印迹聚合物（IIP）材料因对所需金属离子具有强大的选择性而赢得了广泛的认可。因此，通过使用金属a与ox肟肟配体作为络合剂来制备离子印迹聚合物（Ce-IIP），此外，乙二醇二甲基丙烯酸酯（EGDMA）和2,2-偶氮二异丁腈（AIBN）是交联剂和自由基引发剂， 分别。应用HCl水溶液从印迹聚合物中浸出铈离子，以形成模板腔，该模板可用于进一步以高选择性吸附铈离子。Ce-IIP的特点是使用ICP-MS，FE-SEM以及通过紫外可见NIR光谱进行的固态分析。FT-IR研究证实Ce-IIP的络合是成功的。发现最佳pH为6，最高吸附容量估计为约145mg g-1。因此，制得的Ce-IIP在镧系元素离子的存在下对铈离子具有非常好的选择性，并且Ce-IIP可以重复使用10次，而吸附能力没有实质性损失。

  DOI：

  10.1166/jnn.2019.16538

文献信息

• Pyridin-3-yl derivatives as immunomodulating agents
  申请人：Bolli Martin

  公开号：US20100168005A1

  公开（公告）日：2010-07-01

  The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 ; R 6 and A are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及Formula (I)中的吡啶-3-基衍生物，其中R1、R2、R3、R4、R5、R6和A如描述中所述，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• Pyridin-4-yl derivatives as immunomodulating agents
  申请人：Bolli Martin

  公开号：US20100063108A1

  公开（公告）日：2010-03-11

  The invention relates to pyridine derivatives of Formula (I) wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及公式（I）中的吡啶衍生物，其中A、R1、R2、R3、R4、R5和R6如描述中所述，它们的制备以及它们作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。
• Bis-aryloxadiazoles as effective activators of the aryl hydrocarbon receptor
  作者：Kaitlin J. Basham、Vasudev R. Bhonde、Collin Kieffer、James B.C. Mack、Matthew Hess、Bryan E. Welm、Ryan E. Looper

  DOI：10.1016/j.bmcl.2014.04.013

  日期：2014.6

  Bis-aryloxadiazoles are common scaffolds in medicinal chemistry due to their wide range of biological activities. Previously, we identified a 1,2,4-bis-aryloxadiazole that blocks mammary branching morphogenesis through activation of the aryl hydrocarbon receptor (AHR). In addition to defects in mammary differentiation, AHR stimulation induces toxicity in many other tissues. We performed a structure activity relationship (SAR) study of 1,2,4-bis-aryloxadiazole to determine which moieties of the molecule are critical for AHR activation. We validated our results with a functional biological assay, using desmosome formation during mammary morphogenesis to indicate AHR activity. These findings will aid the design of oxadiazole derivative therapeutics with reduced off-target toxicity profiles. (C) 2014 Elsevier Ltd. All rights reserved.
• PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2069335A1

  公开（公告）日：2009-06-17
• PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2069336A1

  公开（公告）日：2009-06-17